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Abstract 
3D spheroids of immortalized cell lines and primary human cells were utilized to 
examine the structure-function relationship of lipid nanoparticles (LNPs).  Establishing a 
rigorous procedure for HepG2 and Hep3b spheroids included determination of 
appropriate seeding densities and media conditions for LNP transfection.  
Experimentation with standard and non-standard LNP formulations highlighted 
significant variation with cell and culture type, thus suggesting that choosing 
appropriately is of the utmost importance.  Furthermore, it was noted that LNP 
performance should be determined via evaluation in multiple metrics since potency and 
maximum expression results did not always align.  An in vitro to in vivo correlation with 
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Nucleic acids are a promising therapeutic for the treatment of many diseases via modified gene 
expression and subsequent protein production [1–3].  These results can be achieved via the 
introduction of a variety of nucleic acids, such as mRNA, siRNA, and anti-sense 
oligonucleotides.  An mRNA-based therapy allows gene expression to occur relatively quickly, 
in as few as 4-6 hours after dosing because mRNA can be translated to a protein product without 
entering the nucleus [1,4].  However, in order for these therapies to be effective, sensitive nucleic 
acid cargoes must be delivered undamaged to their target site, necessitating a drug delivery 
method that fully shields the cargo from degradation following therapeutic administration and 
biodistribution.  Lipid nanoparticles (LNPs) fully encapsulate their cargo molecules until uptake 
occurs in target cells; providing mRNA-cargo protection from degradation and shielding from 
potential immune response [1–3].  Lipid components within LNPs can be varied to control 
particle size, particle stability, cargo encapsulation, and endosomal escape [2,5–7].  After 
intravascular administration, LNPs are extracted from plasma via first-pass metabolism in the 
liver.  By nature of their lipid composition, LNPs are then bound by serum-derived 
Apolipoprotein E and targeted to low density lipoprotein receptors on the hepatocellular surface, 
thus triggering internalization and delivery [2].   
 
As with most biopharmaceutical candidates, LNPs are often tested in vitro prior to introduction 
in in vivo models.  Screening of biopharmaceutical candidates in vitro is most commonly 
conducted with immortalized cell lines cultured in 2D monolayers.  This practice is well-
established, inexpensive, high-throughput, and often a prerequisite to further experiments in 
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vivo.  However, identifying successful biopharmaceutical candidates with this screening 
methodology hinges on a correlation between in vitro and in vivo results.   Immortalized cell 
lines have characteristic mutations that allow them to be replicated and grown indefinitely in 
vitro, however, these mutations also naturally distinguish them from their counterparts in live 
tissues.  Recent studies highlight the lack of significant correlation between in vitro and in vivo 
results, suggesting that current screening standards may be insufficient or misleading, and often 
resulting in inappropriate identification of lead hits [8,9]. With consideration to the structure and 
function relationship of lipid components in LNPs, Kulkarni et al. show that for delivery of 
pDNA an unsaturated fatty acid as a helper lipid performs better than a saturated fatty acid in 
vitro, however, the opposite is seen in vivo (i.e. a saturated fatty acid helper lipid has superior 
performance than an unsaturated fatty acid).  Similar paradoxical results have been observed 
when varying other lipid components of LNPs [10,11]. These contradictory results in vitro and in 
vivo are just one example of the lack of an in vitro to in vivo correlation (IVIVC), and thus 
inefficiency in current biopharmaceutical screening standards.  
 
This lack of an IVIVC is likely due to the dissimilarities observed for immortalized cell lines in 
2D culture as compared to their originating tissues [8].  In 2D culture, immortalized cell lines 
exhibit limited cell-to-cell interactions and migration, as well as differential adhesion, polarity, 
and morphologies [12].  These dissimilarities can be overcome by in vitro testing in primary cells 
[13,14], but this is often very costly, resource intensive, and highly variable.  3D spheroid 
cultures of immortalized cell lines exhibit intercellular signaling, transport, morphological, and 
biochemical similarities to tissues in vivo and may offer a promising alternative [15–
17].  Furthermore, 3D spheroids have been recognized as an especially useful model in oncology 
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due to their different layers of proliferation and hypoxic core [17,18].  These characteristics 
suggest that screening with 3D spheroids may offer more accurate predictive results of 
biopharmaceutical candidates than screening in 2D culture, while remaining relatively 
inexpensive and high-throughput.  
 
Through examining the structure-function relationship of LNPs in 2D and 3D cell culture 
and in vivo models, we hypothesize that LNP-mRNA transfections in 3D cultures are more 
predictive of in vivo transfection.  Since LNPs exhibit preferential innate targeting for delivery 
to the liver [2], in vitro experiments include immortalized hepatocellular cell lines HepG2 and 
Hep3b, and primary human hepatocytes.  
 
Examining an IVIVC has the potential to significantly decrease research and development 
timelines and costs for new therapeutics [3].  This benefits patients by making cutting-edge 
therapeutic options available sooner at lower prices.  Furthermore, an IVIVC correlation has the 
potential to decrease the need for animal testing in drug development research, thus further 
decreasing time, cost, and animal lives needed for developing new therapeutics.  
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Materials and Methods 
Additional information and/or examples can be found in the Supplementary Information.  
Cell Growth and Handling 
HepG2 and Hep3b 2D Cell Culture:  Media for HepG2 was prepared via the combination of 500 
mL DMEM, 50 mL FBS, and 5 mL 100x MEM NEAA.  This solution was mixed well and 
filtered to remove any particulates.  Media for Hep3b was prepared with 50 mL MEM + 
GlutaMax, 50 mL FBS, 5 mL NEAA, and 5 mL sodium pyruvate.  This solution was mixed well 
and filtered to remove any particulates.  Cells were plated in Corning 96-well tissue-treated flat-
bottom plates at seeding densities of 60,000 cells/well in 100 µL total volume with their 
respective media.  Plates were placed in an incubator (37±2 °C, 5±1% CO2, ≥85% RH) for 24 
hours to allow cells to attach.  24 hours after cell seeding plates were transfected with LNPs. 
 
 HepG2 and Hep3b 3D Cell Culture:  Media for HepG2 and Hep3b cells was prepared as 
described above.  Cells were plated in Corning 96-well ultra-low attachment u-bottom plates at 
seeding densities of 3,000 cells/well in 100 µL total volume with their respective media.  
 
Primary Human Hepatocytes 2D Cell Culture:  Primary human hepatocytes and plating media 
components were obtained from both Corning and ThermoFisher as available.   The plating 
media was prepared by the combination of 500 mL Williams E, 5 mL Corning ITS Supplements, 
5 µL 10 mM dexamethasone, 7.5 mL HEPES, 5 mL Penn/Strep/Glut, and 50 mL FBS.  Cells 
were thawed and dispersed in plating media.  Cells were then counted with a Vi-Cell and plated 
in ThermoFisher 96-well tissue-treated flat-bottom plates at densities of 20,000 cells/well.  Plates 
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were placed in an incubator  (37±2 °C, 5±1% CO2, ≥85% RH) for 24 hours to allow cells to 
attach.  24 hours after cell seeding plates were transfected with LNPs. 
 
Primary Human Hepatocytes 3D Cell Culture:  Primary human hepatocytes and plating media 
components were obtained from both Corning and ThermoFisher as available.   Cells were then 
prepared according to manufacturer’s instructions [19], with some adaptations.   Plating media 
was prepared as described above.  Cell maintenance media was also prepared at this time by 
combining 500 mL Williams E, 5 mL Corning ITS Supplements, 5 µL 10 mM dexamethasone, 
7.5 mL HEPES, and 5 mL Penn/Strep/Glut.  Both the plating and maintenance media were 
filtered to remove any particulates.   
 
Cells were thawed and dispersed in plating media.  Cells were then counted with a Vi-Cell and 
plated in ThermoFisher 96-well U-bottom Nunclon Sphera plates at densities of 2,000 cells/well 
in a total volume of 100 µL.  Plates were centrifuged at 100xg for 2 minutes to facilitate early 
aggregation.  Plates were placed in an incubator  (37±2 °C, 5±1% CO2, ≥85% RH) for 48 hours.  
 
After 48 hours, and additional 100 µL of maintenance media was added to each well.  Plates 
were centrifuged at 100xg for 2 minutes and returned to incubator. 
 
96 hours after initial cell seeding 100 µL of media was removed from each well and replaced 
with 100 µL of fresh maintenance media. Approximately 168 hours after cell seeding plates were 
transfected with LNPs. 
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Lipid Nanoparticle Formulation 
Lipid nanoparticles were prepared via the combination of two solutions in a microfluidic 
device.  The volumetric ratio of solutions during the mixing process was 1:3 organic to aqueous.  
Organic solutions (Cholesterol, PEG-DMG, helper lipid, ionizable lipid) were prepared via the 
suspension of lipid components in ethanol and thorough mixing.  Aqueous solutions (RNA-se 
free water, Citrate Buffer, and mRNA) were prepared with sterile technique in Biological Safety 
Cabinet.  Lipid and mRNA solutions were then loaded in independent syringes and LNP 
formulations were prepared using a NanoAssemblr mixing device from Precision Nanosystems 
(PNI, Canada).  LNP formulations were collected and analyzed for their size, charge, 
polydispersity, mRNA percentage encapsulation efficiency, and mRNA content.   
 
A table with additional details concerning LNP formulation and characterization details can be 
found in the Supplementary Information.  
  
Lipid Nanoparticle Characterization 
Ribogreen Assay:  Performed a 2% dilution by combining naked mRNA with Tris-EDTA buffer. 
A standard curve for mRNA luminescence was built in a 96-well plate.  Aliquots of the standard 
curve were divided amongst four columns of wells, where additional Tris-EDTA buffer or Triton 
X were added for a total volume of 200 µL.   
 
To determine the mRNA content and mRNA encapsulation efficiency, LNPs were then diluted to 
2% via combination with Tris-EDTA buffer and mixed well.  50 µL of each LNP dilution was 
added to four wells, with Tris-EDTA or Triton X buffer added.  The Ribogreen solution was 
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prepared by performing a 5% dilution in Tris-EDTA buffer and mixing well.  100 µL of 
Ribogreen working solution was added to each well (mRNA standards and LNP samples), mixed 
well, and inspected for bubbles.   
 
Fluorescence reading was evaluated via a microplate reader with excitation at 495 nm and 
emission at 525 nm.  The standard curve values were then plotted for extrapolation of mRNA 
sample concentrations.   
 
RP-HPLC:  Following LNP concentration calculations, HPLC samples were prepared at 30 
µg/mL (based on mRNA) in Tris-EDTA, with 50% total volume Triton X added.  Hybrid LNP 
samples were prepared similarly, except substituting 8mM SDS buffer for Tris-EDTA.  Samples 
were ran in sequence to monitor potential mRNA degradation in relation to an mRNA standard.   
 
Malvern Zeta-sizer:  To determine the average size of mRNA encapsulated LNPs, a 0.4% 
dilution of LNP particles in PBS was performed and gently mixed.  A 70 µL sample was 
transferred to a quartz cuvette for data collection.  Through calculations considering the diffusion 
and Brownian motion of particles, size measurement was calculated via a Stokes-Einstein 
relationship.   
 
To determine the zeta potential of mRNA encapsulated LNPs, a 0.1% dilution of LNP particles 
in 10mM NaCL NaP detergent solution.  The sample was loaded into a disposable zeta potential 
cuvette for measurement via Laser Doppler Micro-electrophoresis.  
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Lipid Nanoparticle Transfection 
LNPs were warmed to room temperature and mixed by gentle pipetting with filtered pipette tips. 
LNPs were diluted to appropriate concentrations (10 µg working mRNA / mL for 2D cultures, 
40 µg working mRNA / mL for 3D cultures).  For transfection in 2D cultures, a high 
concentration of 500 ng final mRNA per well with six subsequent two-fold dilutions was 
prepared.  For transfection in 3D cultures, a high concentration of 2000 ng final mRNA per well 
with nine subsequent two-fold dilutions was prepared. 
 
For 2D plates, 50 µL of each LNP dilution was added to appropriate wells.  Then an appropriate 
volume of media to transfection and blank wells was added for a total volume of 200 µL. 
 
For 3D plates, 50 µL of media was removed from transfection wells, this amount was replaced 
with 50 µL appropriate LNP dilution solutions. 
 
All plates were returned to incubator (37±2 °C, 5±1% CO2, ≥85% RH).  A Steady-Glo assay to 
measure luminescence signal resulting from mRNA transcription and Luciferase protein 
production resulting from successful transfection was performed 24 hours after 
transfection.  Prior to Steady-Glo assay, plates were removed from incubator to equilibrate to 
room temperature and imaged with Incucyte.  
 
Steady-Glo assay was performed according to manufacturer’s instructions, with a shaking period 
of 20 minutes, and brief monitoring under the microscope to ensure cells are sufficiently 
detached or disrupted.  
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For luminescence reading, 100 µL from each well was transferred to white-walled plates and 
read via Perkin Elmer Envision. 
Results and Discussion 
I. Development of 3D Spheroid Growth Protocols 
Previous literature on the development of 3D spheroid models characterizes cells in one of four 
categories:  single cell suspensions, loose aggregates, compact aggregates, and spheroids (Figure 
1) [13,20–22].  It is also well-known that spheroids consist of three different inner layers:  the 
proliferative zone, the quiescent zone, and the necrotic core.  These zones arise in part due to 
limited oxygen and nutrient diffusivity through layers of cells, thus defining the cells’ metabolic 
state [16,23].   At this time, there is no defined standard cell seeding density to optimize the 
balance between necrotic core size in relation to overall spheroid morphology for in vitro studies 
[21], and optimal seeding densities are likely cell line and media dependent.  For these reasons, 
while developing our 3D spheroid growth protocols, we examined different media conditions 
and seeding densities. 
 
Figure 1. Understanding spheroid morphology classification and different metabolic layers of activity.  




 a. Immortalized Hepatocellular Cell Line: HepG2s 
Many researchers seed HepG2 spheroid culture in media containing fetal bovine serum 
(FBS), then transition to serum-free media to eliminate potential particulates and sources 
of variability to encourage consistently compact spheroids [13,21,23,24].  Others suggest 
that when human-derived cell lines, including such as HepG2 cells, are cultured in human 
serum (HS), they tend to form tighter, more compact spheroids than when cultured in 
FBS [20] with improved cell functionality and better metabolism of lipids 
[25].  Increased metabolism of lipids may result in increased transfection efficiency.  The 
HS condition in these studies also included a variety of supplements, in order to more 
closely resemble cellular contact with interstitial fluid [20].  In order to determine which 
conditions yielded the best spheroids, we examined different spheroid seeding densities, 












When comparing spheroids maintained in serum to spheroids transitioned from serum to 
serum-free conditions over a period of 5 days, we noted that spheroid viability decreased 
Figure 2.  Comparing spheroid viability in different media conditions.   Spheroids of different 
seeding densities were either maintained in FBS or transitioned to serum-free media.  RLUs refers 
to relative luminescent units, i.e. the intensity of luminescence induced as a result of cellular ATP 
facilitating reaction with luciferase, thus reflecting cellular viability. 12 replicates were evaluated 
for each sample; error bars are representative of 95% confidence interval.  
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when transitioned to serum-free conditions, regardless of seeding density (Figure 
2).  Additionally, spheroids of larger seeding densities appeared to have more irregular, 
asymmetric morphology than spheroids of smaller seeding densities (Figure 3).  In order 
to culture spheroids with simple spherical morphology, and to decrease overall area of a 









A comparison of HepG2 spheroids cultured in media containing FBS or media containing 
HS, revealed different apparent spheroid densities - as exhibited by color differences in 
Figure 4.  Some previous research has suggested that coloration is a reflection of 
spheroid density, i.e. darker appearance corresponds with more cells [23], however, this 





Figure 4.  Different apparent spheroid 
densities.  Images collected via Incucyte 
imaging. 
Left:  HepG2 spheroid cultured in FBS.  
Right:  HepG2 spheroid cultured in HS 
Figure 3. A visual comparison of spheroid morphology collected via Incucyte imaging.  Panels A-E are 
HepG2 spheroids of different seeding densities (500, 1,000, 2,000, 5,000, and 10,000 cells/well) 
maintained in media with constant levels of fetal bovine serum.  Panels F-J are HepG2 spheroids of 
different seeding densities (500, 1,000, 2,000, 5,000, and 10,000 cells/well) maintained in serum-free 
media. Lower right hand bar is time-stamp.  Spheroids were cultured in 12 replicates.   
A B C E 




Regardless, HepG2 spheroid morphology remained consistently “compact aggregate” 
independent of changes in culture conditions.  Over a five-day period, HepG2 spheroids 
cultured in either FBS or HS exhibited comparable viability values, as shown in Figure 
5.  Viability was also consistent with different spheroid seeding densities – HepG2  
spheroids seeded at 1,000 cells per well had less overall luminescence signal than 
spheroids seeded at 5,000 cells per well, indicating a higher number of overall cells in the 
larger seeding density.  This suggests that the necrotic core is not impacting the overall 
viability of the spheroids, i.e. both 1,000 and 5,000 cell seeding densities do not illustrate 
significant interference due to necrosis.  When evaluated after 8 days in culture, 
spheroids cultured in both FBS and HS demonstrated a decrease in viability; however, 
spheroids cultured in FBS appear to decrease more than spheroids cultured in HS (Figure 
5).  These results suggest that if HepG2 spheroids are going to be used for any 
Figure 5. Monitoring spheroid viability after culture in Fetal Bovine Serum (FBS) and Human Serum (HS) 
conditions.  After 5 days in culture spheroids have comparable viability regardless of culture conditions.  
After 8 days in culture there appear to be significant differences in spheroid viability, however both have 
declined markedly.  RLUs refers to relative luminescent units, i.e. the intensity of luminescence induced as a 
result of cellular ATP facilitating reaction with luciferase, thus reflecting cellular viability.10 replicates were 
evaluated for each sample; error bars are representative of 95% confidence interval    
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experimentation for eight days or more, it is beneficial to consider culture in media 
containing HS. 
To examine if HS conditions impacted transfection of spheroids with LNPs, as suggested 
through the lipid metabolism findings by Pramfalk et al., spheroids were transfected with 
LNPs containing enhanced Green Fluorescent Protein (eGFP) mRNA, and resulting 
eGFP expression was measured using an IncuCyte high-content fluorescent microscope 
housed in a cell culturing incubator.  Using the IncuCyte to measure fluorescence allowed 
quantitation of eGFP expression in near real time, while cells were kept in their optimal 
environment.  Transfection with eGFP LNPs was monitored immediately following 
dosage, with expression detected as early as 8 hours post-transfection (Figure 6).  
Maximum eGFP expression was attained at approximately 48 hours, with additional time 















































Figure 6.  Time course for eGFP expression in HepG2 3D 
spheroids following administration of a 500 ng mRNA dose.  
Protein expression was measured in near real time via Incucyte 
imaging.  15 replicates were evaluated for each sample; error 
bars are representative of 95% confidence interval  
 
Time Course for GFP Expression 
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Examination of eGFP LNP dose response in media containing FBS shows significant 
toxicity in the high dose of 2000 ng mRNA, resulting in a large hook (Figure 7).  Minor 
toxicity accompanied the 1000 ng mRNA dose, with the 500 ng mRNA dose exhibiting 
the highest expression without toxicity.  These results suggest that optimal mRNA dosage 












After maximum eGFP expression was observed, cells were measured for post-
transfection viability. Post-transfection viability was comparable across seeding densities 
and between FBS and HS conditions (Figure 8).  This suggests that overall spheroid 
viability post-transfection was not adversely impacted by either media condition.   































Dose Response for LNP A1 
HepG2 3D
Dose Response for eGFP LNPs 
Figure 7.  Dose response for eGFP LNPs in HepG2 3D spheroids 
cultured in media containing FBS.  Hook effect is evident.  Data 
shown is from 1 replicate evaluated; error bars are representative 











However, upon closer examination of different eGFP LNP dosages to HepG2 spheroids 
in different culture conditions, some LNP transfection-induced cytotoxicity is evident 
(Figure 9).  For spheroids cultured in media containing FBS, cytotoxicity was observed 
with the highest 2000 ng mRNA dose, but at lower concentrations eGFP was expressed 
in a dose dependent fashion.  For spheroids cultured in media containing HS, there was 
no evident cytotoxicity.  At the 2000 ng, the highest levels of eGFP expression were 
observed, however lower dosages showed much lower eGFP expression than seen in the 
FBS counterpart.  These results suggest that in HS media conditions, eGFP LNPs are 





Figure 8.  Comparing spheroid viability after transfection with eGFP LNPs.  RLUs 
refers to relative luminescent units, i.e. the intensity of luminescence induced as a 
result of cellular ATP facilitating reaction with luciferase, thus reflecting cellular 
viability.  15 replicates were evaluated for each sample; error bars are representative 












Via compilation of dose response curves, potency values for LNPs in different media 
conditions were calculated.  Figure 10 shows that transfection in media containing HS is 
significantly less potent than transfection in media with FBS.  This data, with the findings 
from Figure 9, illustrate that transfection in HS is less potent and less dose dependent 









Figure 9. Green fluorescence intensity over 48 hour time interval as shown via 
plate layout.  Column 1 was an untransfected control, column 2-5 were 
transfected with 2000,1000, 500, and 250 ng mRNA doses respectively.  
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Figure 10.  Dose response for HepG2 3D spheroids in media containing FBS or 
HS.  A rough calculated EC50 for the FBS condition is 662 ng mRNA, and 8e10 for 




Timed imaging showed eGFP activity penetrating inward from the perimeter of the 
spheroid (Video in Supplemental Figures), which is logical, as the spheroid perimeter is 
directly exposed to the solution containing LNPs.  HepG2 spheroid morphology after 
transfection with eGFP LNPs is shown in Figure 11.  Spheroids did not dissociate with 
any LNP dosage, remaining distinctly compact aggregate.  Figure 11 also demonstrates 
higher fluorescent intensity in the perimeter of the spheroid, as compared to the core, 
again illustrating transfection starting at the spheroid perimeter and eventually bleeding 






Since culture and maintenance of spheroids in HS did not exhibit more “spheroidal” 
morphology or increased viability than spheroids cultured and maintained in FBS, and an 
FBS/HS comparison showed lower potency and less dose-dependence in media 
containing HS, we proceeded with FBS for culture. Additionally, as the transition to 
serum-free conditions adversely impacted spheroid viability without significant 
improvement in spheroid morphology, we decided to conduct spheroid culture in medium 
with constant levels of FBS (i.e. no transition to serum-free).  FBS is commonly used in 
cell culture technique, widely available, and relatively inexpensive, thus this decision 
supports an accessible and high-throughput methodology for future use. 
 
Figure 11. HepG2 spheroids (maintained 
in media with FBS, 5,000 cells / well) 48 
hours after eGFP LNP transfection.  
“Compact aggregate” morphology is 
evident. Cells are from plate shown in 
Figure 9, treated with 1000 ng and 500 ng 
respectively.  Images collected via 
Incucyte imaging.  Spheroids 
approximated 1000 µm in diameter.  
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b. Immortalized Hepatocellular Cell Line:  Hep3bs 
Although HepG2s and Hep3bs are both derived from hepatocytes, they show 
significantly different protein expression (identity and levels) from human liver models 
and each other [26,27].  This suggests that experimentation with HepG2 and Hep3b cells 
may yield different results when examining a potential IVIVC.  Furthermore, HepG2 and 
Hep3bs cells are often used in mechanistic studies to understand drug metabolism [28].  
In order to adapt our 3D spheroid protocol for HepG2s to Hep3bs, we cultured Hep3bs in 
similar conditions to HepG2s.  The only adaptations to our protocol were changes to base 
media composition specific for Hep3bs, but FBS was maintained at the same 
concentration as HepG2 culture.  Cultured Hep3bs formed spheroids within 24-48 hours, 
exhibiting tighter, more compact structure than HepG2 spheroids (Figure 11 and Figure 
12).  Moreover, eGFP expression timing and patterns in Hep3b spheroids were similar to 
HepG2s, with detectable levels of expression observed starting at 8 hours and plateauing 






c. Primary Human Hepatocytes 
Primary human hepatocyte spheroids were cultured directly from cryopreservation 
according to the manufacturer’s protocol, as described in the Methods section 
Figure 12. Hep3b spheroids 
(maintained in media with 
FBS, 3,000 cells / well) 48 
hours after eGFP LNP 
transfection.  Morphology is 
distinctly spheroidal. Images 
collected via Incucyte 
imaging.  Spheroids 
approximated 600 µm in 
diameter.  
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above.  These spheroids exhibited “compact aggregate” morphology with an observable 
number of satellite cells that did not participate in spheroid formation (Figure 13).  We 
believe that these satellite cells are not viable cells, as total viability of primary human 
hepatocytes following thaw from cryopreservation is typically between 70 and 80%.  
Efforts were made to monitor satellite cell viability via Annexin Red, however PHH 
autofluorescence was noted as a confounding factor (shown in Supplemental Figures).  
PHH also exhibited autofluorescence under green light, and were therefore not 
transfected with eGFP LNPs to visualize LNP transfection through the spheroid.  For 
additional studies with PHH, we used luciferase mRNA instead of eGFP to eliminate any 





 II. Lipid Nanoparticle Design 
a. Standard LNPs 
In order to thoroughly test different LNP compositions within our 2D, 3D, and in vivo 
models, we designed a set of standard LNPs that consist of PEG-DMG, cholesterol, 
helper lipid, and ionizable lipid in ratios that have previously shown to be effective.  By 
varying the helper lipid, we sought to examine differences in LNP transfection 
efficiencies previously described by Kulkarni et al [10].   Kulkarni et al. showed that an 
unsaturated helper lipid (DOPC) performed better than a saturated helper lipid (DSPC) in 
Figure 13.  Primary Human 
Hepatocyte spheroids (2,000 
cells / well) .  Morphology 
shows distinct compact 
aggregate with some  separate 
satellite cell colonies.  Images 
collected via Incucyte 
imaging.  Spheroids 
approximated 500 µm in 
diameter.   
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vitro, but the opposite was true with transfections in vivo [10].  By maintaining PEG-
DMG, cholesterol, and ionizable lipid identity and ratios constant and varying the identity 
of helper lipids, we aimed to clarify these contradictory results.  We sought to confirm 
that DOPC and DSPC performed differently when evaluated in traditional 2D culture 
versus in vivo models, and to examine if 3D culture could bridge this gap.   Within our set 
of standard LNPs, LNP A1 serves as our positive control, as it is known as the 
“benchmark” formulation within the field [2,4,10].   
 
Table 1. Composition of Standard LNP Formulations 
 Ionizable Lipid (%) Helper Lipid (%) Cholesterol (%) DMG-PEG (%) 
A1 DLinMC3DMA (50.0%) DSPC (10.0%) 38.5% 1.5% 
A2 DLinMC3DMA (50.0%) DOPC (10.0%) 38.5% 1.5% 
A3 DLinMC3DMA (50.0%) DOPE (10.0%) 38.5% 1.5% 
A4 DLinMC3DMA (50.0%) SOPC (10.0%) 38.5% 1.5% 
A5 DLinMC3DMA (50.0%) Cholesterol (10.0%) 38.5% 1.5% 
 
b. Non-Standard LNPs 
Our non-standard LNPs maintain cholesterol, DMG-PEG, and helper lipid ratios and 
identities, while varying a combination of ionizable lipids.  The ionizable lipid 
combination includes varying amounts of DLinMC3DMA (MC3) and 1,2-dioleoyl-3- 
(trimethylammonium) propane (DOTAP).  MC3 is the newest “gold standard” for 
ionizable lipids, however, previously DOTAP was widely used due to its complexing 
cationic head group and biodegradable character [29,30].  Via combination of MC3 and 
DOTAP, we hope to amplify the favorable qualities of both molecules (complexation, 
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biodegradation), while minimizing the drawbacks associated with individual molecules 
(toxicity). 
Other combinatory lipid nanoparticles have been examined, particularly combining lipid 
and polymer groups.  With some hybrid lipid-polymer nanoparticles, increased 
transfection efficiency is observed [29,31].  We hypothesize that a combinatory lipid-
lipid nanoparticle, may exhibit increased transfection efficiency. 
 
Table 2.  Composition of Non-Standard LNPs 























III. Head to Head Comparison of LNPs In Vitro 
Standard and non-standard LNP formulations loaded with luciferase mRNA were tested in 2D 
and 3D cell cultures across HepG2s, Hep3bs, and PHH, in order to evaluate a possible 
correlation between behavior in 3D and later LNP performance in vivo.  Luciferase expression 
was measured by luminescence 24 hours after each transfection, and results were plotted against 
mRNA concentration in order to calculate EC50 and Emax values to describe potency and 
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maximum expression, respectively.  With comparison of EC50 values across LNP formulations 
and cell culture methods, LNP A1 exhibited a consistently higher potency (lower EC50) than 
other LNPs across all cell lines and conditions, except for PHH 2D and 3D (Table 3, Figure 
14).  These results are consistent with LNP A1’s composition and its status as a “benchmark” 
formulation for previous in vitro, 2D culture studies. 
  
Table 3. EC50 values (ng mRNA) for standard LNPs across cell and culture type.  
 A1 A2 A3 A4 A5 
HepG2 2D 44.64 237.4 216.1 127.3 197.1 
HepG2 3D 50.38 206.8 112.3 243.6 135.4 
Hep3b 2D 67.53 199.7 127.1 274.7 140.6 
Hep3b 3D 81.15 371.5 304.7 165.6 449.3 
PHH 2D 60.22 33.12 41.69 56.98 3.3** 
PHH 3D 182.7 188.4 188.4 137.6 219.7 
 
















        A1      A2                  A3               A4         A5 
Figure 14. A comparison of EC50 values by cell and culture type across each standard LNP formulation.  
LNP A1 is known as the “benchmark” within the field, and accordingly exhibits consistently low EC50 
values.  The calculated value for LNP A5 in PHH 2D was noted to be extremely low and likely 
inaccurate.  In 2D culture 7 replicates were tested, in 3D culture 10 replicates were tested.  Data is from 
3 separate trials.  Error bars represent 95% confidence interval.  









For standard LNP formulations, an increase in EC50 values is observed in PHH from 2D to 3D 
culture conditions.  In four of five standard LNP formulations, EC50 values also increase from 
2D to 3D culture in Hep3bs.  This is consistent with a higher dose necessary for a desired effect 
when transitioning from cellular monolayers or more complex structures.  Since PHH in 2D 
culture are considered the gold standard for their likeness to originating tissues [13,14], these 
results are promising.  With HepG2s, however, there is no apparent trend with the transition from 
2D to 3D culture.  This lack of transition may be due to HepG2s forming loose aggregates in 3D 
cultures, as opposed to tighter spheroid formations observed with Hep3b and PHH 3D cultures.    
 
Evaluation of non-standard LNP formulations does not reveal any trends with EC50 values in 
relation to culture or cell type (Table 4 and Figure 15).  This suggests that transfection results 
are highly dependent on both cell type and LNP formulation. 
 
Table 4.  EC50 values (ng mRNA) for non-standard LNPs across cell and culture type.  For 
some formulations, it was not possible to determine EC50 values due to low efficacy.  
 MX1 MX2 MX3 MX4 
HepG2 2D 120.8 655.1 443.8 ------ 
HepG2 3D 110.5 1329 ------ 724.1 
Hep3b 2D 275.2 678.3 2221 ------ 
Hep3b 3D 552.1 1396 3494 ------ 
PHH 2D 1362 702.9 707.3 1066 














To further analyze LNP performance, Emax values were calculated.  Comparing maximum 
expression values of LNPs at a singular dose is often used to identify well-performing LNPs 
[10,22,32], and thus is a metric that should also be considered in our IVIVC search 
[10,32].  Luminescence counts associated with expression of luciferase mRNA were normalized 
to LNP A1 as the “benchmark” formulation, so to normalize cell number and growth differences 
between HepG2, Hep3b, and PHH that influence absolute luciferase expression.  In the context 
of Kulkarni et al.’s results, LNP A1 contains unsaturated helper lipid DOPC, whereas LNP A2 
contains saturated helper lipid DSPC.  For our transfections in HepG2 cells (2D and 3D), LNP 
A2 exhibits a higher maximum expression than LNP A1 (Figure 16).  When evaluating only 
Emax values, these results show that LNP A2 has higher mRNA expression than LNP A1, and 
could thus be assumed to be more effective, both in 2D and 3D culture.  However, A2 


























Comparing EC50 Values for Non-Standard LNP Formulations 
Figure 15. A comparison of EC50 values by cell and culture type across each non-standard LNP 
formulation.  Data points for several transfections were not able to be determined due to low 
LNP efficacy. In 2D culture 7 replicates were tested, in 3D culture 10 replicates were tested.  
Data is from 3 separate trials.  Error bars represent 95% confidence interval.    
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demonstrated lower potency than A1, as previously mentioned, which also plays a significant 
role in in vivo transfection efficiency.   
 
Examining 2D and 3D culture Emax results across cell types does not highlight any readily 
evident trends – Emax values were sometimes decreased with the transition from 2D to 3D 
culture, and other times increased or remained relatively constant.   PHH 2D cells, the gold-
standard for toxicity studies [14], showed higher expression in LNP A1 than any other standard 
formulation.  However, PHH 3D cells showed higher expression with LNPs A2-A5 than with 
LNP A1.  This suggests that PHH in 3D culture are significantly different than PHH in 2D 
culture, however, the question remains which is more indicative of in vivo results. 
















































































Figure 16.  Normalized Emax values for standard LNPs as compared to LNP A1.  Each cell and 
culture type tested is shown.  In 2D culture 7 replicates were tested, in 3D culture 10 replicates were 
tested.  Data is from 3 separate trials.  Error bars represent 95% confidence interval. 
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When considering normalized Emax values for non-standard LNPs, there are also few obvious 
trends (Figure 17).  LNP MX1 and MX2 successfully transfected each culture type, but seem to 
show highly variability in eMax values across cell and culture types.  Interestingly, LNP MX4 
only appears to significantly transect PHH in 2D culture.  Altogether, the non-standard LNPs 
seem to have high expression values in PHH.   
By considering Emax values alone, LNP MX1 seems as if it might be promising for further 
experimentation.  However, when EC50 values for LNP MX1 are also considered (Table 4), it is 
evident that this LNP has very low potency.  This suggests that it may be valuable to evaluate 
LNPs on more than one metric – as high expression does not always correspond with high 
potency, and vice versa. 
  














































Figure 17.  Normalized Emax values for non-standard LNPs as compared to LNP A1.  Each cell and culture type 
tested is shown.  For unsuccessful transfections, no data is shown. In 2D culture 7 replicates were tested, in 3D 
culture 10 replicates were tested.  Data is from 3 separate trials.  Error bars represent 95% confidence interval.    
or alized Emax Values for Non-Standard LNPs 
 28 
IV. Head to Head Comparisons of LNPs In Vivo  
Significant differences in LNP potency and maximum expression were observed with variation 
of cell and culture types.  LNP transfections within PHH 2D as compared to PHH 3D even 
demonstrated clear differences in regards to potency and efficacy.  Thus, the in vivo 
translatability of cell type and 2D versus 3D culturing remains unclear without conducting an in 
vivo study.  As part of an ongoing study, we selected our standard LNP formulations and a 
negative control to administer to balbC mice.  Our LNPs were loaded with a specific mRNA that 
encodes for therapeutic antibody expression that is easily quantified in mouse serum.   
 
The selected LNPs were formulated as described in Methods, then administered to HepG2, 
Hep3b, and PHH cells in 2D and 3D culture, along with the balbC mice.  Transfection and 
viability data were collected for all cell and culture types, and in vivo data is pending.  
Conclusions and Future Work 
By establishing a rigorous protocol for the culture of HepG2 and Hep3b 3D spheroids, with 
emphasis on seeding density and culture media conditions, we examined a possible IVIVC.    
Manipulating the composition of LNPs showed how some variations in LNP structure impact 
transfection in certain conditions.  With our standard LNP formulations, helper lipid identity 
impacts LNP transfection in all cell and culture types.  For example, transfection with LNP A5 
resulted in less potent transfection as compared to the benchmark LNP A1 as a direct result of 
direct substitution of the helper lipid.  From our research thus far, it is apparent that LNPs 
perform differently in different cell types and culture conditions.  Potency and maximum 
expression were not always congruous, emphasizing the need to evaluate LNPs on both metrics.   
 
These results highlighted a wide array of in vitro results, and thus necessitate an in vivo study to 
clarify potential relationships.   With our continued studies in vivo we hope to examine the 
relationship between transfection in 3D culture and in vivo models to determine if transfection in 























Supplemental Figure 2.  Green 
autofluorescence of a PHH spheroid 
imaged via Incucyte.  
Supplemental Figure 3.  Red 
autofluorescence of PHH cells 
seeded for spheroid formation as 
imaged via Incucyte.  
Supplemental Figure 1.  Time-lapse video 
showing eGFP penetrating the perimeter of a 
HepG2 spheroid and moving inward.  Images 


















Supplementary Figure 4.  
HepG2 cells in 2D culture 24 
hours post-transfection with 
LNPs containing 125 ng 
luciferase mRNA.  Image 
collected via Incucyte.  
Supplementary Figure 5.  
Hep3b cells in 2D culture 24 
hours post-transfection with 
LNPs containing 125 ng 
luciferase mRNA.  Image 




Supplemental Table 1.  Dynamic Light Scattering data for LNP formulations.   
 Average Size (nm) Polydispersity Index Zeta Potential (mV) 
A1 63.14 0.03 -2.06 
A2 68.14 0.05 -0.835 
A3 72.49 0.05 -0.480 
A4 63.52 0.04 -0.172 
A5 70.27 0.02 -0.166 
MX1 48.10 0.17 7.15 
MX2 54.29 0.20 8.20 
MX3 54.10 0.17 7.66 







Supplementary Figure 6.  
Primary Human Hepatocytes in 
2D culture 24 hours post-
transfection with LNPs containing 
125 ng luciferase mRNA.  Image 
collected via Incucyte. 
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Supplemental Table 2.  Average concentration and encapsulation efficiency of mRNA in LNP 
formulations as determined via Ribogreen Assay.   
 Average  
mRNA in LNP (ug/mL) 
Percent 
Encapsulation Efficiency 
A1 310.8 84.7 
A2 235.7 90.8 
A3 287.6 92.1 
A4 334.3 92.2 
A5 324.2 96.7 
MX1 305.2 98.4 
MX2 261.1 75.4 
MX3 185.6 98.9 














Supplemental Figure 7. RP-HPLC analysis for a luciferase mRNA control in 
comparison to encapsulated luciferase mRNA in LNP.  This analysis was 
performed to monitor for potential mRNA degradation.  Luciferase mRNA control 
is plotted in blue, LNP A5 is plotted in magenta.  Aligned peaks suggest that 
mRNA has not degraded.  Intensity of peaks can be further attenuated via careful 










Traditional Dose Response Curve 



































Supplemental Figure 8.  Dose response curve for HepG2 2D culture.  Difficult to attain meaningful and 














































Supplemental Figure 9. Dose response data for LNP formulations in HepG2 2D culture.  Any hook effects 
resulting from LNP toxicity were excluded.  Plotted according to Michaelis-Menten, in order to attribute equal 
weigh to each data point.  Kd values derived from this plot were used as EC50 values for data analysis.   













































Supplemental Figure 10. Dose response data for LNP formulations in HepG2 3D culture.  Any hook effects 
resulting from LNP toxicity were excluded.  Plotted according to Michaelis-Menten, in order to attribute equal 














































Supplemental Figure 11. Dose response data for LNP formulations in Hep3b 2D culture.  Any hook 
effects resulting from LNP toxicity were excluded.  Plotted according to Michaelis-Menten, in order to 
attribute equal weigh to each data point.  Kd values derived from this plot were used as EC50 values for 
data analysis.  Some activity from LNP B2 can be observed – LNP B2 serves as a negative control in all 
other cell types.  
 













































Supplemental Figure 12. Dose response data for LNP formulations in Hep3b 3D culture.  Any hook 
effects resulting from LNP toxicity were excluded.  Plotted according to Michaelis-Menten, in order to 
attribute equal weigh to each data point.  Kd values derived from this plot were used as EC50 values for 














































Supplemental Figure 13. Dose response data for LNP formulations in PHH 2D culture.  Any hook effects 
resulting from LNP toxicity were excluded.  Plotted according to Michaelis-Menten, in order to attribute equal 
weigh to each data point.  Kd values derived from this plot were used as EC50 values for data analysis.    
 












































Supplemental Figure 14. Dose response data for LNP formulations in PHH 3D culture.  Any hook 
effects resulting from LNP toxicity were excluded.  Plotted according to Michaelis-Menten, in order 
to attribute equal weigh to each data point.  Kd values derived from this plot were used as EC50 





















Supplemental Figure 15.  Heat map of LNP standard formulation EC50 data.  Note:  
LNP A5 in PHH 2D had an extremely low EC50 value – upon inspection of the dose 
response curve this data point was categorized as unreliable.   
Comparing EC50 Values for Standard LNP Formulations 
Comparing EC50 Values for Non-Standard LNP Formulations 
 
Supplemental Figure 16. Heat map of LNP non-standard formulation EC50 
values.  Boxes marked with an “x” denote transfections for which no EC50 
could be determined.  
 39 
References  
1.  Rui Y, Wilson DR, Green JJ. Non-Viral Delivery To Enable Genome Editing. Trends 
Biotechnol. 2019; 37: 281–293. 
2.  Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther. 2017; 
25: 1467–1475. 
3.  Buck J, Grossen P, Cullis PR, Huwyler J, Witzigmann D. Lipid-Based DNA Therapeutics: 
Hallmarks of Non-Viral Gene Delivery. ACS Nano. 2019; 13: 3754–3782. 
4.  Yanez Arteta M, Kjellman T, Bartesaghi S, Wallin S, Wu X, Kvist AJ, et al. Successful 
reprogramming of cellular protein production through mRNA delivered by functionalized lipid 
nanoparticles. Proc Natl Acad Sci. 2018; 115: E3351–E3360. 
5.  Tam YYC, Chen S, Cullis PR. Advances in Lipid Nanoparticles for siRNA Delivery. 
Pharmaceutics. 2013; 5: 498–507. 
6.  Kauffman KJ, Robert Dorkin J, Yang JH, Heartlein MW, DeRosa F, Mir FF, et al. Optimization 
of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and 
Definitive Screening Designs. Nano Lett. 2015; pp. 7300–7306.  
7.  Hui SW, Langner M, Zhao YL, Ross P, Hurley E, Chan K. The role of helper lipids in cationic 
liposome-mediated gene transfer. Biophys J. 1996; 71: 590–599. 
8.  Whitehead KA, Matthews J, Chang PH, Niroui F, Robert Dorkin J, Severgnini M, et al. In Vitro–
In Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA Delivery. ACS Nano. 2012; 
pp. 6922–6929.  
 40 
9.  Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, et al. A Direct 
Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of 
Nanoparticles Reveals a Weak Correlation. Nano Lett. 2018; pp. 2148–2157.  
10.  Kulkarni JA, Myhre JL, Chen S, Tam YYC, Danescu A, Richman JM, et al. Design of lipid 
nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomed: Nanotech, Biol Med. 
2017; pp. 1377–1387.  
11.  Farhood, H., Serbina, N., Huang, L. The role of dioleoyl phosphatidylethanolamine in cationic 
liposome mediated gene transfer. Biochim Biophys- Biomemb. 1995; 1235: 289–295. 
12.  Li D-W, He F-L, He J, Deng X, Liu Y-L, Liu Y-Y, et al. From 2D to 3D: The morphology, 
proliferation and differentiation of MC3T3-E1 on silk fibroin/chitosan matrices. Carb Polym. 
2017; pp. 69–77.  
13.  Bell CC, Hendriks DFG, Moro SML, Ellis E, Walsh J, Renblom A, et al. Characterization of 
primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver 
function and disease. Sci Rep. 2016; 6: 25187.  
14.  Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT. Competency of different cell models to 
predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol. 2014; 10: 1553–1568. 
15.  Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, et al. Advances in 
establishment and analysis of three-dimensional tumor spheroid-based functional assays for 
target validation and drug evaluation. BMC Biology. 2012; p. 29.  
 41 
16.  Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their 
applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014; 12: 
207–218. 
17.  Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and challenges for use of 
tumor spheroids as models to test drug delivery and efficacy. J Control Release. 2012; 164: 192–
204. 
18.  Nunes AS, Barros AS, Costa EC, Moreira AF, Correia IJ. 3D tumor spheroids as in vitro models 
to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotech. Bioeng. 2019; pp. 
206–226.   
19.  Corning 3D Spheroid-qualified Primary Human Hepatocytes: Instruction for Primary Human 
Hepatocyte Spheroid Culture (Cat. No. 454552). 6 Henshaw Street Woburn, A 01801: Corning 
Incorporated. 
20.  Heger JI, Froehlich K, Pastuschek J, Schmidt A, Baer C, Mrowka R, et al. Human serum alters 
cell culture behavior and improves spheroid formation in comparison to fetal bovine serum. Exp 
Cell Res. 2018; 365: 57–65. 
21.  Mueller D, Koetemann A, Noor F. Organotypic Cultures of Hepg2 Cells for In Vitro Toxicity 
Studies. J. Bioeng. Biomed Sci. 2011; S2. 
22.  Wallenstein EJ, Barminko J, Schloss RS, Yarmush ML. Serum starvation improves transient 
transfection efficiency in differentiating embryonic stem cells. Biotechnol Prog. 2010; 26: 1714–
1723. 
 42 
23.  Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, et al. 3D tumor spheroid models 
for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of 
data obtained. Sci. Rep. 2016; 6: 19103.  
24.  Hendriks DFG, Fredriksson Puigvert L, Messner S, Mortiz W, Ingelman-Sundberg M. Hepatic 
3D spheroid models for the detection and study of compounds with cholestatic liability. Sci Rep. 
2016; 6: 35434. 
25.  Pramfalk C, Larsson L, Härdfeldt J, Eriksson M, Parini P. Culturing of HepG2 cells with human 
serum improve their functionality and suitability in studies of lipid metabolism. Biochim Biophys 
Acta. 2016; 1861: 51–59. 
26.  Shi J, Wang X, Lyu L, Jiang H, Zhu H-J. Comparison of Protein Expressions between Human 
Livers and the Hepatic Cell Lines HepG2, Hep3B and Huh7 using SWATH and MRM-HR 
Proteomics: Focusing on Drug-Metabolizing Enzymes. Drug Metab Pharmacokinet. 2018; 33: 
133. 
27.  Qiu G-H, Xie X, Xu F, Shi X, Wang Y, Deng L. Distinctive pharmacological differences 
between liver cancer cell lines HepG2 and Hep3B. Cytotechnology. 2015; 67: 1. 
28.  Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent 
advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte 
sources and non-parenchymal liver cells and their use in investigating mechanisms of 
hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013; 87: 1315. 
29.  Xue HY, Guo P, Wen W-C, Wong HL. Lipid-Based Nanocarriers for RNA Delivery. Curr 
Pharm Des. 2015; 21: 3140. 
 43 
30.  Kurzchalia TV, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, et al. VIP21, a 21-kD 
membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J 
Cell Biol. 1992; 118: 1003–1014. 
31.  Xue HY, Narvikar M, Zhao J-B, Wong HL. Lipid Encapsulation of Cationic Polymers in Hybrid 
Nanocarriers Reduces Their Non-Specific Toxicity to Breast Epithelial Cells. Pharm Res. 2013; 
30: 572–583. 
32.  Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, et al. Degradable lipid 







Johns Hopkins University          Aug. 2018 – Dec. 2019 
 Anticipated Graduation:  December 2019 
 Area of Study: Chemical and Biomolecular Engineering, Master of Science in 
Engineering 
Pacific Lutheran University                    Aug. 2014 – May 2018 
 Graduated May 2018, cum laude 
 Area of Study: Chemistry, Bachelor of Science, Biology, Bachelor of Science 
 Study Away Spring, 2017:  University of Namibia  
 
Graduate Research Experience: 
INBT Coop Internship – Johns Hopkins University and AstraZeneca      Jan. 2019 – July 2019 
 Research Mentors:  Dr. J Luis Santos (AZ), Dr. G Patrick Hussmann (AZ), Dr. Jordan J 
Green (JHU)  
 Research Focus:  Implementing in vitro screening tools for evaluating novel mRNA-
nanoparticulate formulations  
 Developed a thorough protocol for the culture of immortalized hepatocellular lines as 3D 
spheroids  
 Synthesized nanoparticle formulations for drug delivery via microfluidic technology   
 Characterized nanoparticle formulations via Reverse-Phase Liquid Chromatography, 
Ribogreen fluorescence assay, and with a Malvern Zeta-Sizer  
 45 
 Designed and performed experiments to examine a possible in vitro in vivo correlation:  
including lipid nanoparticle transfection of cells, eGFP monitoring, Steady-Glo and Cell-
Titer Glo luminescence assays  
Johns Hopkins Center for a Livable Future and World Wildlife Fund       Oct 2018 – Jan 2019 
 Research Mentors:  Dr. Roni Neff, Dr. Jillian Fry, Dr. Dave Love, Erin Biehl 
 Research Focus:  Addressing seafood waste by promoting frozen purchasing 
 Identified and contacted retail seafood organizations in the Baltimore, Maryland area to 
interview 
 Conducted qualitative interviews with retail seafood staff in order to understand seafood 
sustainability   
 Transcribed qualitative interviews and identified important preliminary findings 
 Reported interview findings to principle investigators for manuscript compilation   
Undergraduate Research Experience: 
Natural Sciences Summer 2017 Undergraduate Research Program             June 2017 – Aug. 2017 
 Research Mentor:  Dr. Andrea M. Munro 
 Research Focus:  Synthesis of Mn:ZnSe/ZnS nanocrystals and ligand exchange 
 Synthesized CdSe and ZnSe nanocrystals using air-free techniques 
 Used SILAR techniques to grow spherical shells on CdSe nanocrystals 
 Characterized products via FTIR, NMR, and XRD 
 Facilitated ligand exchange, characterized with FTIR and NMR 
 Continued research in Dr. Munro’s lab throughout the academic year, ending in May 
2018 
 46 
Organic Special Projects Laboratory        Feb. 2016 – May 2016 
 Research Mentor:  Dr. Neal A. Yakelis 
 Research Focus:  Development of aryldiborate weakly coordinating dianions  
 Attempted synthesis via Grignard attack in an air-free environment  
 Characterized products and quantified relative yield via GC-MS 
Other Relevant Laboratory Experience: 
Determination of concentration with Inductively Coupled Plasma Atomic Emission Spectroscopy 
Spectrophotometric analysis via UV-Visible Spectroscopy 
Super-critical fluid extraction  
Determination of unknown mixture with Thin Layer Chromatography 




Spring 2018 Biology Capstone Symposium                May 2018 
 Oral Presentation:  Kisspeptin as a modulator of sexual behavior in rodents 
2018 Chemistry Capstone Symposium                 May 2018 
 Oral Presentation:  Improving luminescent solar concentrator efficiency using doped 
nanocrystals and ligand exchange 
26th Annual Murdock College Science Research Conference              Nov. 2017 
 Poster Presentation:  Improving luminescent solar concentrator efficiency using doped 
nanocrystals and ligand exchange 
Natural Sciences Summer Undergraduate Research Presentations              Sept. 2017 
 47 
 Oral Presentation:  Improving luminescent solar concentrator efficiency using doped 
nanocrystals and ligand exchange 
Murdock Collaborative Research Alliance Collaborative Meeting            June 2017 
 Oral Presentation:  Nanocrystals:  Exploring diffusion doping, shells, and ligand 
exchange 
PLU Natural Sciences Academic Festival Poster Session                           May 2016 
 Poster Presentation:  Development of aryldiborate weakly coordinating dianions 
ACS Puget Sound Undergraduate Research Symposium                           Apr. 2016 
 Poster Presentation:  Development of aryldiborate weakly coordinating dianions 
 
Clinical Shadowing Experience 
Medstar Promptcare at Alexandria         May 2019 – July 2019 
 Shadowed Dr. E. Kate Snodgrass 
 Observed diagnosis and treatment of bacterial and viral infections, injuries, and long-term 
health concerns 
Vic’s Family Pharmacy                  Aug. 2016 
 Shadowed Dr. Victor Allen 
 Observed retail, long-term care, and compound pharmacy techniques 
 Earned “HIPPA” and “Fraud, Waste, and Abuse” Certifications 
Lovelace and Kido Dental           Jan. 2014 – May 2014 
 Shadowed Dr. Lori Lovelace and Dr. Scott Kido 




Johns Hopkins Children’s Hospital             Sept. 2019 – Present 
Maryland SPCA               Oct. 2018 – Present 
Hope Village Orphanage           Jan. 2017 – May 2017 
Sherman Elementary School          June 2011 – Aug. 2014 
Lighthouse Rescue Mission          Aug. 2013 – May 2014 
 
 
Honors and Awards: 
Pacific Lutheran University -- Ramstad Scholar (2017) 
Pacific Lutheran University -- Dean’s List (Aug. 2014 – May 2018) 
Idaho High School State Athletics Association -- Track and Field State Qualifier (2014) 
Skyview High School -- Student Leadership Award (2014) 
Skyview High School -- Junior Varsity Women’s Soccer Captain (2011-2013) 
